Operational excellence at scale: Why integrated manufacturing is the future biopharmaceutical standard

Conventional, siloed manufacturing models are becoming outdated as the industry adapts to tighter regulations and shifting dynamics. CDMOs that implement end-to-end, integrated operations stay ahead of headwinds and lead to timely batch releases toward continuous client satisfaction.
The latest International Biopharmaceutical industry article by Kevin Sharp, EVP & Head of Sales and Operations, highlights how the integrated manufacturing model positions CDMOs to offer three competitive advantages to clients.

Conventional, siloed manufacturing models are becoming outdated as the industry adapts to tighter regulations and shifting dynamics. CDMOs that implement end-to-end, integrated operations stay ahead of headwinds and lead to timely batch releases toward continuous client satisfaction.
The latest International Biopharmaceutical industry article by Kevin Sharp, EVP & Head of Sales and Operations, highlights how the integrated manufacturing model positions CDMOs to offer three competitive advantages to clients.
Share article
Related Content